乳腺癌患者术前采用吡柔比星、环磷酰胺联合多西他赛方案治疗的近远期疗效及安全性分析

Short and Long Term Efficacy and Safety of Pirarubicin and Cyclophosphamide Combined with Docetaxel Regimen in Patients with Breast Cancer before Operation

目的:探讨乳腺癌患者术前采用吡柔比星、环磷酰胺联合多西他赛(TAC)方案治疗的近远期疗效及安全性。方法:选取2013年1月—2015年1月我院收治的110例乳腺癌患者,按随机数字表法分为两组,各55例。对照组单纯实施手术治疗,观察组术前采用TAC新辅助化疗方案,再实施手术治疗,比较两组手术切除率、近期疗效、癌因性疼痛评分、中远期存活率、局部复发率、生存质量评分。结果:观察组手术切除率、客观缓解率、总有效率均高于对照组,差异有统计学意义(P <0.05);治疗后,观察组静息疼痛评分、运动疼痛评分均低于对照组,差异有统计学意义(P <0.05);观察组1年存活率、3年存活率均高于对照组,术后1年、3年局部复发率均低于对照组,差异有统计学意义(P <0.05);随访1年、3年时,观察组生理健康、心理健康、社会功能、总体感觉等生存质量评分均高于对照组,差异有统计学意义(P <0.05)。结论:在乳腺癌患者手术治疗前行TAC方案新辅助化疗,可有效提高患者的手术切除率,减轻癌因性疼痛,有利于提高近期疗效,还可有效改善患者远期预后和生存质量,减少局部复发,安全性可靠。

Objective:To explore the short and long term efficacy and safety of preoperative pirarubicin and cyclophosphamide combined with docetaxel(TAC)regimen in patients with breast cancer.Methods:110 patients with breast cancer admitted to our hospital from January 2013 to January 2015 were selected and randomly divided into two groups,55 cases each.The patients in the control group were treated by operation alone,and the patients in the observation group were treated by TAC neoadjuvant chemotherapy before operation.The surgical resection rate,short-term efficacy,cancer-related pain scores,medium-and long-term survival rate,local recurrence rate and quality of life were compared between the two groups.Results:The surgical resection rate,objective remission rate and total effective rate in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the resting pain scores and exercise pain scores in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The 1-year survival rate and 3-year survival rate in the observation group were higher than those in the control group,and the local recurrence rates 1 year and 3 years after operation were lower than those in the control group,with statistically significant differences(P<0.05).After 1 year and 3 years of follow-up,the quality of life,such as physical health,mental health,social functions and overall sensation in the observation group was higher than that in the control group,with statistically significant differences(P<0.05).Conclusion:TAC regimen neoadjuvant chemotherapy for breast cancer patients before operation can effectively improve surgical resection rate,reduce cancer pain,improve short-term efficacy,effectively improve long-term prognosis and quality of life and reduce local recurrence,and is safe and reliable.